1 © Igor Fisch 2013 All Rights Reserved. © Copyright 2013 Selexis SA. All rights reserved.

Innovation through Clustering

with regard to Biotechnology

and

Life Science

Igor Fisch, PhD

Chairman and CEO, Selexis SA

2 © Igor Fisch 2013 All Rights Reserved.

Agenda

1. Innovation in Switzerland: How to stimulate innovation and bring it to the market: the example of Venture Kick initiative

2. Clustering in Biotech: Is this a necessity? One example of bio-incubators in Geneva 3. Private experience starting and running businesses

Selexis SA BioXpress Therapeutics SA Viroblock SA Stemergie Biotechnology SA Affitech A/S

4. Discussions

3 © Igor Fisch 2013 All Rights Reserved.

Innovation in Switzerland

Switzerland has a leading role in innovation and competitiveness

1. ICT 2. Electronics/Mechanics 3. Medtech 4. Lifescience (Biotech)

5. Cleantech 6. Micro-/Nanotechnology 7. Materials/Chemicals 8. Others

4 © Igor Fisch 2013 All Rights Reserved.

Venture Kick: Stimulation of Entrepreneurship

Philanthropic initiative launched by Swiss Foundations

Gebert Rüf Foundation Ernst Göhner Foundation Avina Foundation OPO Foundation Lombard Odier Foundation DebioPharm group

Pre-seed fund aiming at promoting and speeding-up new start-ups in the overall high-tech environment in Switzerland

Double the number of spin-offs In the midterm we want to double the number of spin-off projects from Swiss Universities.

Cut time-to-market by half We want to significantly speed up the process of structuring business opportunities and startup companies.

Improve the quality of spin-off projects We want to substantially improve the quality of projects in terms of Executed VC and Business Angel-Investments.

5 © Igor Fisch 2013 All Rights Reserved.

Venture Kick: How Does it Work?

A strong governance geared towards results

Management Team

Beat Schillig

Co-managing

director

Jordi Montserrat

Co-managing

director

Strategic Board

Dr. Igor Fisch

SELEXIS SA

Dr. Roger Schmid

ERNST GÖHNER

STIFTUNG

Dr. Pascale Vonmont

GEBERT RÜF

STIFTUNG

6 © Igor Fisch 2013 All Rights Reserved.

Venture Kick: The Process

7 © Igor Fisch 2013 All Rights Reserved.

Venture Kick: The Results (2007-2013)

Over 1’200 applications since September 2007

Over 600 candidates presented

302 projects received 11’020’000 CHF

Over 210 startup companies incorporated (180 still active)

57 venture kickers made it to the TOP 100 SWISS STARTUPS

Over 2’000 new jobs created (FTEs)

365’000’000 CHF in financing raised by the venture kickers

8 © Igor Fisch 2013 All Rights Reserved.

Is Clustering a Necessity?

9 © Igor Fisch 2013 All Rights Reserved.

The Clustering Effect: e.g. FONGIT Incubator

Mission Facilitate innovation and economic value creation

Incubator Founding, hosting & growing HighTech start-ups

Industries CleanTech, ICT, IT, medTech, nanotech

Collaborations CTI, and financing oganisations

Offices hosting 20+ tech companies in 3000 m2 furnished space

Services administration, accounting, financial, company foundation

Team 4 experimented coaches

Financing Fongit Seed Invest- up to 500 k CHF per company

La Fondation Genevoise pour l’Innovation Technologique (FONGIT)

10 © Igor Fisch 2013 All Rights Reserved.

The Clustering Effect: e.g. FONGIT Incubator

Incubator in Geneva grouping > 30 companies

Selexis SA (since 2001)

BioXpress Therapeutics SA (since 2010)

Viroblock SA (since 2005)

Help in Start-up phase

Help growing and managing company

Stemergie Biotechnology SA (since 2012)

Affitech A/S (2010-2012)

11 © Igor Fisch 2013 All Rights Reserved.

The Clustering Effect: my Experience 1/4

Since 2001

Biotech comp. developing production tools for the industry

Impact on COGS for manufacturing recombinant protein drugs (EPO,

Mabs)

Break-even in 2005

18 FTEs

Patent portfolio: 137 granted, 30 pending and 3 provisional

> 40 products in clinical trials, manufactured with Selexis’ technologies

12 © Igor Fisch 2013 All Rights Reserved.

The Clustering Effect: my Experience 2/4

Since 2005

Biotech company developing products to fight pathogenic viral infections

Product efficient against all types of enveloped viruses (e.g. influenza, HIV,…)

Product positioned to deliver topical anti-viral products (such as masks)

13 © Igor Fisch 2013 All Rights Reserved.

The Clustering Effect: my Experience 3/4

Philosophy: all patients should have access to safe and high-quality biologic

therapeutics at affordable costs.

Products: high-quality biosimilar biologic APIs for unmet need indications such

as cancer, inflammation and autoimmunity

Mission: Cost-competitive biosimilar biologic API (MAb and MAb-like biosimilar

drugs) to the highest EMA safety and quality standards.

Since 2005

14 © Igor Fisch 2013 All Rights Reserved.

The Clustering Effect: my Experience 4/4

15 © Igor Fisch 2013 All Rights Reserved.

Discussions